Virtu Financial LLC Has $964,000 Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Virtu Financial LLC trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 36.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,128 shares of the medical equipment provider's stock after selling 5,337 shares during the period. Virtu Financial LLC's holdings in Zimmer Biomet were worth $964,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at $25,000. Dunhill Financial LLC raised its position in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 218 shares in the last quarter. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet during the 3rd quarter valued at about $35,000. Kentucky Trust Co acquired a new position in shares of Zimmer Biomet in the 4th quarter worth approximately $39,000. Finally, OFI Invest Asset Management bought a new stake in shares of Zimmer Biomet in the 4th quarter worth approximately $40,000. 88.89% of the stock is owned by institutional investors.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.95% of the stock is owned by corporate insiders.

Remove Ads

Zimmer Biomet Price Performance

Zimmer Biomet stock traded down $1.48 during trading hours on Tuesday, hitting $109.76. 523,151 shares of the stock were exchanged, compared to its average volume of 1,496,400. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The stock has a market capitalization of $21.85 billion, a P/E ratio of 24.67, a P/E/G ratio of 1.95 and a beta of 1.04. The business's 50-day moving average is $106.86 and its two-hundred day moving average is $106.86. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the company earned $2.20 EPS. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is currently 21.57%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ZBH shares. Raymond James cut their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. JMP Securities restated a "market outperform" rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Royal Bank of Canada reduced their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. raised shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.